According to the Zhixun Finance APP, CSPC Pharma (01093) has risen by more than 3% as of press time, with an increase of 3.15%, and the stock price is HKD 6.55, with a turnover of HKD 200 million.

In terms of news, CSPC Pharma announced that its first hybrid antigen receptor (CAR)-T cell injection based on mRNA-LNP developed by the group (SYS6020) has been approved by the National Medical Products Administration for clinical trials in China. The approved clinical indication for this application is multiple myeloma (MM). In addition, this product has the potential to be used in the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) and myasthenia gravis (MG).

It is reported that this product is the world's first mRNA-LNP-based cell therapy product approved for clinical trials. Pre-clinical studies have shown that the product can significantly kill BCMA antigen-positive myeloma cells and has good safety and efficacy.